Alpha-2 Macroglobulin Is The Simplest Serum Biomarker For Liver Fibrosis And Fibrogenesis In Chronic Hepatitis C

Atanasova, Evelina; Martinova, Fani; Jelev, Deyan; Antonov, Krasimir; Mey, Christian de; Mateva, Lyudmila; Krastev, Zahary

doi:10.18044/medinform.201522.153

Cited by 4 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The GR-MD-02 8-mg/kg treatment group had a significant reduction in FibroTest Scores, a composite of five individual blood tests that collectively correlate with the extent of liver fibrosis. The reduction was most attributed to the lowering of α-2 macroglobulin, a major non-immunoglobulin protein in plasma that is known to have a role in inhibiting proteases including collagenase [129] FibroScan evaluations were performed at baseline, day 38, and day 65 in a subset of patients (five from GR-MD-02 group and three from placebo group). No observed change in liver stiffness was seen in the three placebo patients; however, three of the five patients treated with GR-MD-02 showed a 20% reduction in liver stiffness from baseline.…”

Section: Competitive Environmentmentioning

confidence: 99%

Promising therapies for treatment of nonalcoholic steatohepatitis

Noureddin

Zhang

Loomba

2016

Expert Opinion on Emerging Drugs

View full text Add to dashboard Cite

Introduction-Non-alcoholic fatty liver disease (NAFLD) has become the most common etiology for abnormal aminotransferase levels and chronic liver disease. Its growing prevalence is largely linked to the presence of metabolic syndrome, particularly diabetes and insulin resistance. It is estimated that 60-80% of the type 2 diabetic population has NAFLD. NAFLD encompasses a range of conditions ranging from simple steatosis to nonalcoholic steatohepatitis (NASH). A subset of patients with hepatic steatosis progress to NASH, while 15-20% of patients with NASH develop cirrhosis. This progression is thought to be multifactorial, and there are currently no FDAapproved medications for the treatment of NASH.

show abstract

Section: Competitive Environmentmentioning

confidence: 99%

Promising therapies for treatment of nonalcoholic steatohepatitis

Noureddin

Zhang

Loomba

2016

Expert Opinion on Emerging Drugs

View full text Add to dashboard Cite

show abstract

“… 16 , 25 α 2 M is a protease inhibitor, which is produced by the liver and locally synthesised by macrophages, adrenocortical cells and fibroblast and part of the innate immune system. 26 In humans, α 2 M has been demonstrated to play an important role in maintaining homeostasis of cytokines and growth factors. 27 Increased α 2 M plasma levels have consistently been seen during periods of life characterized by growth, development, and differentiation such as embryogenesis, pregnancy, and childhood.…”

Section: Introductionmentioning

confidence: 99%

“… 27 Increased α 2 M plasma levels have consistently been seen during periods of life characterized by growth, development, and differentiation such as embryogenesis, pregnancy, and childhood. 26 , 28 …”

Section: Introductionmentioning

confidence: 99%

Influence of α2-Macroglobulin, Anti-Parasite IgM and ABO Blood Group on Rosetting in Plasmodium falciparum Clinical Isolates and Their Associations with Disease Severity in a Ghanaian Population

Bandoh

Kyei-Baafour

Aculley

et al. 2022

JBM

View full text Add to dashboard Cite

Purpose The severity of Plasmodium falciparum infections is associated with the ability of the infected red blood cells to cytoadhere to host vascular endothelial surfaces and to uninfected RBCs. Host blood group antigens and two serum proteins α 2 -macroglobulin (α 2 M) and IgM have been implicated in rosette formation in laboratory-adapted P. falciparum . However, there is only limited information about these phenotypes in clinical isolates. Methods This was a hospital-based study involving children under 12 years-of-age reporting to the Hohoe Municipal Hospital with different clinical presentations of malaria. Parasite isolates were grown and rosette capabilities and characteristics were investigated by fluorescence microscopy. α 2 M and IgM were detected by ELISA. Results Rosette formation was observed in 46.8% (75/160) of the parasite isolates from all the blood groups tested. Rosettes were more prevalent (55%) among isolates from patients with severe malaria compared to isolates from patients with uncomplicated malaria (45%). Rosette prevalence was highest (30%) among patients with blood group O (30%) and B (29%), while the mean rosette frequency was higher in isolates from patients with blood group A (28.7). Rosette formation correlated negatively with age (r = −0.09, P= 0.008). Participants with severe malaria had a lower IgM concentration (3.683±3.553) than those with uncomplicated malaria (5.256±4.294) and the difference was significant (P= 0.0228). The mean concentrations of anti-parasite IgM measured among the clinical isolates which formed rosettes was lower (4.2 ±3.930 mg/mL), than that in the non rosetting clinical isolates (4.604 ±4.159 mg/mL) but the difference was not significant (P=0.2733). There was no significant difference in plasma α 2 M concentration between rosetting and non rosetting isolates (P=0.442). Conclusion P. falciparum parasite rosette formation was affected by blood group type and plasma concentration of IgM. A lower IgM concentration was associated with severe malaria whilst a higher α 2 M concentration was associated with uncomplicated malaria.

show abstract